Evidence map›Paper›PMID 31976323›Full record

ArticleBioMed research international2019

Rapid Affinity Maturation of Novel Anti-PD-L1 Antibodies by a Fast Drop of the Antigen Concentration and FACS Selection of Yeast Libraries.

Biancamaria Cembrola, Valentino Ruzza, Fulvia Troise, Maria Luisa Esposito, Emanuele Sasso, Valeria Cafaro, Margherita Passariello, Feliciano Visconte, Maddalena Raia, Luigi Del Vecchio and 6 more

Open access · hybridAbstract read
In one paragraph

Article in BioMed research international, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Biancamaria CembrolaDepartment of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Via S. Pansini 5, 80131 Naples, Italy.ORCID https://orcid.org/0000-0001-6439-1176
Valentino RuzzaNouscom s.r.l., Via di Castel Romano 100, 00128 Rome, Italy.
Fulvia TroiseCEINGE-Biotecnologie Avanzate s.c.a r.l., Via G. Salvatore 486, 80145 Naples, Italy.
Maria Luisa EspositoReithera s.r.l., Via di Castel Romano 100, 00128 Rome, Italy.
Emanuele SassoDepartment of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Via S. Pansini 5, 80131 Naples, Italy.
Valeria CafaroDepartment of Biology, University of Naples Federico II, Cupa Nuova Cintia 21, 80126 Naples, Italy.ORCID https://orcid.org/0000-0002-6686-7657
Margherita PassarielloDepartment of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Via S. Pansini 5, 80131 Naples, Italy.
Feliciano VisconteCEINGE-Biotecnologie Avanzate s.c.a r.l., Via G. Salvatore 486, 80145 Naples, Italy.
Maddalena RaiaCEINGE-Biotecnologie Avanzate s.c.a r.l., Via G. Salvatore 486, 80145 Naples, Italy.
Luigi Del VecchioDepartment of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Via S. Pansini 5, 80131 Naples, Italy.
Anna Morena D'AliseNouscom s.r.l., Via di Castel Romano 100, 00128 Rome, Italy.
Riccardo CorteseNouscom s.r.l., Via di Castel Romano 100, 00128 Rome, Italy.
Elisa ScarselliNouscom s.r.l., Via di Castel Romano 100, 00128 Rome, Italy.
Nicola ZambranoDepartment of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Via S. Pansini 5, 80131 Naples, Italy.ORCID https://orcid.org/0000-0001-9395-3481
Claudia De LorenzoDepartment of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Via S. Pansini 5, 80131 Naples, Italy.ORCID https://orcid.org/0000-0002-6195-5631
Alfredo NicosiaDepartment of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Via S. Pansini 5, 80131 Naples, Italy.
Ceinge Biotecnologie Avanzate (Italy) · ITNouscom (Italy) · ITUniversity of Naples Federico II · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The affinity engineering is a key step to increase the efficacy of therapeutic monoclonal antibodies and yeast surface display is the most widely used and powerful affinity maturation approach, achieving picomolar binding affinities. In this study, we provide an optimization of the yeast surface display methodology, applied to the generation of potentially therapeutic high affinity antibodies targeting the immune checkpoint PD-L1. In this approach, we coupled a 10-cycle error-prone mutagenesis of heavy chain complementarity determining region 3 of an anti-PD-L1 scFv, previously identified by phage display, with high-throughput sequencing, to generate scFv-yeast libraries with high mutant frequency and diversity. In addition, we set up a novel, faster and effective selection scheme by fluorescence-activated cell sorting, based on a fast drop of the antigen concentration between the first and the last selection cycles, unlike the gradual decrease typical of current selection protocols. In this way we isolated 6 enriched mutated scFv-yeast clones overall, showing an affinity improvement for soluble PD-L1 protein compared to the parental scFv. As a proof of the potency of the novel approach, we confirmed that the antibodies converted from all the mutated scFvs retained the affinity improvement. Remarkably, the best PD-L1 binder among them also bound with a higher affinity to PD-L1 expressed in its native conformation on human-activated lymphocytes, and it was able to stimulate lymphocyte proliferation

Indexed as

Antibodies, MonoclonalAntibody AffinityB7-H1 AntigenBase SequenceCell LineCell ProliferationComplementarity Determining RegionsFlow CytometryHigh-Throughput Nucleotide SequencingHumansImmunoglobulin GLymphocytesMutagenesisPeptide LibrarySaccharomyces cerevisiaeSingle-Chain AntibodiesAntibodies, MonoclonalB7-H1 AntigenCD274 protein, humanComplementarity Determining RegionsImmunoglobulin GPeptide LibrarySingle-Chain Antibodies

Identifiers

PMID31976323
PMCPMC6959147
OpenAlexW2997135462

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.